Another IGF2BP2 inhibitor, CWI1-2, effectively inhibits leukemia in vivo by targeting MYC, glutamate pyruvate transaminase 2 (GPT2) and SLC1A5 mRNAs, leading to a drastic downregulation of mitochondria-related glutamine metabolic pathways and energy production [91]. The gene discussed is GPT2; the disease is leukemia.